期刊
KIDNEY INTERNATIONAL
卷 99, 期 1, 页码 34-47出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.10.012
关键词
alburninuria; chronic kidney disease; cost-effectiveness; creatinine; cystatin; detection; kidney failure; glomerular filtration rate; health systems; interventions; proteinuria; risk models; risk stratification; screening
资金
- KDIGO
- Akebia Therapeutics
- AstraZeneca
- Bayer HealthCare
- Boehringer Ingelheim
- Cricket Health
- CVS Kidney Care
- Fresenius Medical Care
- Gentian
- Janssen
- Kyowa Kirin
- Mundipharma
- Reata
- Relypsa
- Tricida
Chronic kidney disease (CKD) is a significant global burden associated with higher morbidity and mortality, especially among individuals with lower socioeconomic status. Despite the availability of guidelines for evaluating and managing early CKD, there is still a lack of consensus on prioritizing early identification and intervention for CKD without incentives or quality measures.
Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prioritize early identification and intervention for CKD. Guidelines on evaluating and managing early CKD are available but have not been universally adopted in the absence of incentives or quality measures for prioritizing CKD care. The burden of CKD falls disproportionately upon persons with lower socioeconomic status, who have a higher prevalence of CKD, limited access to treatment, and poorer outcomes. Therefore, identifying and treating CKD at the earliest stages is an equity imperative. In 2019, Kidney Disease: Improving Global Outcomes (KDIGO) held a controversies conference entitled Early Identification and Intervention in CKD. Participants identified strategies for screening, risk stratification, and treatment for early CKD and the key health system and economic factors for implementing these processes. A consensus emerged that CKD screening coupled with risk stratification and treatment should be implemented immediately for high-risk persons and that this should ideally occur in primary or community care settings with tailoring to the local context.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据